Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
June 19, 2020

A closer look at Regeneron and its efforts to provide the world with a Covid-19 treatment

By Jamie Bell

Like many firms in the pharmaceutical sector, Regeneron has turned a great deal of attention towards the fight against Covid-19 in recent weeks and months.

Having already entered one of its existing drug therapies into clinical studies to test its efficacy against the virus, Regeneron has also announced the start of trials for a novel antibody cocktail, which could help treat hospitalised patients, or prevent Covid-19 in uninfected people.

We take a closer look at the US biotech firm, and its ongoing attempts to uncover an effective treatment for the novel coronavirus.

Read the full article here.

Related Companies

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy